Abstract
Among endocrine disruptors, the xenoestrogen bisphenol A (BPA) is of particular interest due to the very high production and widespread environmental contamination. We recently demonstrated that the oral administration of BPA to mice results in the formation of DNA adducts not only in liver but also in mammary tissue. The present study aimed at evaluating the modulation of BPA-related DNA adducts and proteome alterations by the chemopreventive agents budesonide (BUD) and phenethyl isothiocyanate (PEITC). Swiss ICR (CD-1) mice received, for 8 days, BPA with the drinking water and either chemopreventive agent with the diet. We measured DNA adducts by 32P postlabeling and 656 proteins by antibody microarray. BPA induced the formation, with similar patterns, of DNA adducts in liver and in mammary tissue. Moreover, BPA dysregulated 13 proteins in mammary tissue, mostly in the sense of upregulation, including estrogen receptor-β and proteins involved in cell proliferation, inhibition of apoptosis, tissue remodeling, inflammation, stress response, and glutathione synthesis. PEITC significantly inhibited the formation of BPA-induced DNA adducts, but only at the highest dose tested, and BUD was totally ineffective. The chemopreventive agents modulated a variety of BPA-induced changes in proteome profiles. However, as shown by both hierarchical cluster analysis and principal component analysis, BUD and especially PEITC were not able to restore the physiological situation in BPA-treated mice. Therefore, the in vivo use of proteome analysis proves to be a sensitive tool for the early prediction not only of protective effects but also of adverse effects of chemopreventive agents.
Keywords: Budesonide, phenethyl isothiocyanate, bisphenol A, mice, liver, mammary tissue, DNA adducts, proteome
Current Cancer Drug Targets
Title: Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
Volume: 10 Issue: 2
Author(s): A. Izzotti, M. Longobardi, C. Cartiglia, F. D'Agostini, S. Kanitz and S. De Flora
Affiliation:
Keywords: Budesonide, phenethyl isothiocyanate, bisphenol A, mice, liver, mammary tissue, DNA adducts, proteome
Abstract: Among endocrine disruptors, the xenoestrogen bisphenol A (BPA) is of particular interest due to the very high production and widespread environmental contamination. We recently demonstrated that the oral administration of BPA to mice results in the formation of DNA adducts not only in liver but also in mammary tissue. The present study aimed at evaluating the modulation of BPA-related DNA adducts and proteome alterations by the chemopreventive agents budesonide (BUD) and phenethyl isothiocyanate (PEITC). Swiss ICR (CD-1) mice received, for 8 days, BPA with the drinking water and either chemopreventive agent with the diet. We measured DNA adducts by 32P postlabeling and 656 proteins by antibody microarray. BPA induced the formation, with similar patterns, of DNA adducts in liver and in mammary tissue. Moreover, BPA dysregulated 13 proteins in mammary tissue, mostly in the sense of upregulation, including estrogen receptor-β and proteins involved in cell proliferation, inhibition of apoptosis, tissue remodeling, inflammation, stress response, and glutathione synthesis. PEITC significantly inhibited the formation of BPA-induced DNA adducts, but only at the highest dose tested, and BUD was totally ineffective. The chemopreventive agents modulated a variety of BPA-induced changes in proteome profiles. However, as shown by both hierarchical cluster analysis and principal component analysis, BUD and especially PEITC were not able to restore the physiological situation in BPA-treated mice. Therefore, the in vivo use of proteome analysis proves to be a sensitive tool for the early prediction not only of protective effects but also of adverse effects of chemopreventive agents.
Export Options
About this article
Cite this article as:
Izzotti A., Longobardi M., Cartiglia C., D'Agostini F., Kanitz S. and De Flora S., Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A, Current Cancer Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/156800910791054220
DOI https://dx.doi.org/10.2174/156800910791054220 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility
CNS & Neurological Disorders - Drug Targets The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets The Role of LncRNA TUG1 in Obesity-related Diseases
Mini-Reviews in Medicinal Chemistry Caveolin-1 in Cell Migration and Metastasis
Current Molecular Medicine Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors
Current Medicinal Chemistry Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Hypomagnesaemia/Hypokalemia Associated with the Use of Esomeprazole
Current Drug Safety A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) The Use of Nimesulide and Its Analogues in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry